Hormone receptor-positive, HER2-negative breast cancer

Hormone receptor-positive, HER2-negative breast cancer, whose tumor cells carry receptors for estrogen or progesterone and do not overexpress HER2, is the most common breast cancer subtype: about 70% of female breast cancer cases in the United States, at 92.9 new cases per 100,000 women a year (SEER, 2019–2023) (NCI SEER Cancer Stat Facts: Female Breast Cancer Subtypes).
In this portal you'll find an overview of the disease, market maps, and maps of the ecosystem around it.

HR+/HER2− BC at a glance: 172 active programs; 137 discontinued programs; 136 companies with programs, past or present; 292 private investors in these companies; 37 of the 50 largest pharma companies active in HR+/HER2− BC; 86 funding, data and partnering opportunities (data as of 3 Nov 2026).

Market maps

Ecosystem